【摘要】 目的 探讨肺动脉高压患者药物靶向治疗的效果与耐受性。 方法 回顾分析2008年1月〖CD3/5〗2009年8月期间8例肺动脉高压患者分别接受波生坦及西地那非治疗的临床资料,评估其临床表现、WHO肺动脉高压功能分级、6 min步行距离及肺动脉收缩压在基线及治疗3个月后的变化。 结果 治疗后3个月,患者均能耐受药物治疗,无严重不良反应发生。WHO肺动脉高压功能分级在治疗前平均(31±04),治疗后为(23±09),明显得到改善(P lt;005)。肺动脉收缩压在治疗前平均(695±112 ) mm Hg(1 mm Hg=0133 kPa),治疗后为(483±124) mm Hg,明显降低(P lt;005)。6 min步行距离在治疗前平均(324±48) m,治疗后为(400±43) m,明显延长(P lt;005)。 结论 肺动脉高压患者药物靶向治疗的疗效显著,且耐受良好。
【Abstract】 Objective To examine the effects of target medical therapy in patients with pulmonary arterial hypertension(PAH). Methods To determine the safety and efficacy of bosentan and sildenafil in eight patients with PAH.The patients’ clinical features, six minutes walking diastance, WHO functional class and systolic pulmonary arterial pressure (SPAP) were measured at baseline and at three months after initiating target medial treatment. Results At the three months followup assessments, WHO functional class was improved with 31±04 vs 23±09 (P lt;005); SPAP was significantly decreased with(695±112 ) mm Hg vs (483±124) mm Hg (P lt;005), the six minutes walking distance was significantly increased with(324±48) m vs(400±43) m (P lt;005). Target medical treatment was well tolerated. Conclusion Target medical treatment is well tolerated and has beneficial effects on PAH.

Citation： nts with Pulmonary Arterial HypertensionWTBXCUI Kaijun,FENG Yuan,JIANG Lingyun,XU Yuanning.. Clinical Study of Effects of Target Medical Therapy in Eight Patients with Pulmonary Arterial Hypertension. West China Medical Journal, 2010, 25(4): 662-. doi: Copy